● Recruiting

The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4

Condition: Stargardt · Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University

PhaseEARLY_Phase 1

Planned participants9

Who can joinAll sexes, 8 Years to no upper limit

Healthy volunteersNo

About this study

To evaluate the preliminary safety of monocular and single subretinal injection of ZVS106e injection in the treatment of patients with hereditary retinal degeneration (ABCA4-IRDS) caused by ABCA4 biallelic mutations.

This description comes directly from the study's public registry record.

Talk to the study team

dayou Ding · 010-82266699 · dingdayou@chinagene.cc

Always discuss trial participation with your own doctor first.

Locations (2)

Peking University Third Hospital	Beijing, Beijing Municipality, China	Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University	Guangzhou, Guangdong, China	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07241169